Lilly to Acquire Novartis Animal Health
President of Elanco Animal Health Jeff Simmons says the acquisition of Novartis will result in providing more diversified brands, reach more market segments expand Elanco’s global footprint as well as strengthen the pipeline, capabilities and expertise of the company.
Simmons: “We’re creating a global leader in animal health — a number two company. We believe we are going to be a leader in innovation. We’re going to focus heavy on new products, new innovations taken to the market place that ultimately add more customer value. That is whats worked with the pipeline and the last seven transactions and that’s what we see doing with this one. So how we are going to do that is really combining the best of two companies.”
The transaction will close by end of the first quarter of next year. As far as seeing any changes seen here in the Pacific Northwest, to personnel or representatives that probably won’t likely be happening in the near future.
Upon completion of the current acquisition, Elanco will be the second-largest animal health company in terms of global revenue, will solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world.